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High throughput screening (HTS) involves using automated
equipment to test a large number of samples against a defined
molecular target to identify a reasonable number ofactive molecules
in a timely fashion. Major factors which can influence priorities
for the limited resources of the HTS group are projects,
productivity, progress and people. The challenge to the HTS
group is to provide excellent and timely screening services, but still
devote efforts to new technologies and personnel development. This
article explains why these factors are so important.
Introduction
Automated high throughput screening (HTS) in the
pharmaceutical industry has become a valuable resource
to search for proprietary chemical structures which inter-
act with novel biomolecular targets such as enzymes,
cellular receptors or ion channels. Under some circum-
stances these chemicals may serve as leads which can be
optimized into marketable drugs. To maximize success it
is necessary to use HTS resources in a manner which
complements and facilitates the changing priorities of
drug discovery research. The enormous medical benefits
associated with bringing a novel drug to market provide
an incentive to complete all steps in the drug discovery
process, including HTS, as quickly and efficiently as
possible.
Numerous institutions and individuals involved in the
discovery and development of a new drug possess unique,
changeable and sometimes conflicting priorities. Some of
these participants include the FDA, the marketplace,
research departments within the pharmaceutical com-
pany, individual scientists and HTS team members.
Since it is never possible to do everything--in HTS or
any other aspect of real life--priorities are needed to
make the best choices. Four major factors which can
influence priorities are:
Projects.
Productivity.
Progress.
People.
Long-term success depends upon creating a balance
among all these factors. The purpose of this paper is to
highlight the importance of each in providing an ex-
cellent high throughput screening service within a large
pharmaceutical company.
Projectsmchoosing the best molecular target
The human genome consists of tens of thousands of gene
products--proteins such as enzymes, receptors, ion chan-
nels and growth factors--which are important for main-
taining good health, if not life itself. Many of these gene
products are likely to play a role in disease and, therefore,
have the potential to be a molecular target for pharma-
cological intervention. Before HTS resources can be
applied to discover chemicals which can interact with
any of these specific molecular targets, the decision must
be made as to which gene products represent the best
targets to pursue.
The process of initiating a project around a particular
target (or targets) is difficult to generalize. Some drug
discovery research groups may be organized around a
therapeutic area, such as cardiovascular or inflammatory
diseases, while others might focus on classes of molecular-
based mechanisms such as 7-transmembrane domain
receptors or signal transduction cascades. A wide range
of factors, from proprietary scientific expertise through
existing market franchises, must be evaluated to deter-
mine which general classes of targets to examine. Even if
a general area is accepted as important for pharmacolo-
gical intervention, there is no single approach to identify
the best molecular target. For example, the many en-
zymes involved in cholesterol synthesis were well known
and studied for decades before the first successful drug
which inhibited only one of the enzymes was discovered.
Once a specific molecular target has been selected, a
great deal of hard work is necessary to determine how
best to apply HTS resources to find leads which modulate
the activity associated with this target. Research might
indicate that a particular gene--for example, a cell-sur-
face receptor--is found in greater abundance in certain
diseases. A high throughput screen might be created
which looks for molecules which decrease the transcrip-
tion of the gene for this receptor. Or, a screen might be
created which seeks molecules which prevent the binding
of the natural ligand to this receptor. Or, a screen might
be created which inhibits the intracellular messages that
occur subsequent to activation of the cell surface recep-
tor. In other words, even if a single interesting molecular
target can be identified, there are several potential
screening approaches available for testing and these
options need to be prioritized.
Setting priorities should take advantage of the three
perspectives required to create a successful HTS, namely:
Pharmacology and physiology.
Biophysics and biochemistry.
Automation and robotics.
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The three perspectives on HTS do not agree on all
matters, but each is essential to success.
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The pharmacology and physiology views must come from
the scientists in the therapeutic area who are familiar
with the pathologic role of the chosen molecular target. It
is useful to know the conditions under which the target
protein functions. For example, knowing the concentra-
tions of natural ligands, substrates and cofactors in both
the healthy and diseased states is important because they
reflect the conditions under which the future drug must
work. This type of information may suggest, for example,
that inhibition of ligand binding is likely to be a more
effective therapy that reduction in transcription.
Biophysics and biochemistry contribute to determining
the feasibility of assembling a valid assay which can be
developed into a high throughput screen. It is essential
that the interactions be examined in detail to understand
the effects of time, temperature and reagent concentra-
tions on kinetic parameters, such as initial rates of
enzymes or equilibrium binding constants. These metrics
can be used both to maintain consistently high quality of
different batches of key reagents as well as to select assay
conditions which mimic the true pathologic situation and
minimize interassay variability.
The automation and robotics perspective takes into
account the available HTS resources to produce a screen
with maximum signal to noise which can be performed
with maximum throughput. This may require elimin-
ation of tedious manual steps, or temperature changes,
which might produce artifacts such as condensation or
uneven heating rates of samples with microtitre plates.
The three perspectives on HTS (pharmacology and
physiology; biophysics and biochemistry, automation
and robotics) may recommend different assay designs,
but each must make compromises to create a single
screen which can be ultimately successful.
Prioritizing a high throughput screen based upon the
target (the project) makes sense in light of the scientific
strengths and marketing goals of the pharmaceutical
company. When the best target is identified, it is still
necessary to know enough about the circumstances of the
disease state and the biophysical properties of the target
protein to understand how to design a viable assay. The
nature of the assay must impact the priority of the
project, however, because some screens are easier to
perform or are best suited to the available HTS people
and hardware.
Productivityresearch by numbers
High throughput screening groups are generally evalu-
ated on the basis of productivity numbers. The most
common measures are:
Screens-the number run per year or how many are
performed simultaneously.
Time lines--time to develop a screen, finish it or
deliver results.
Throughput--the number of samples tested per week.
Samples--the total number of entities (compounds or
extracts) tested.
Hit rate--the number of active samples found com-
pared to expected rate.
Although all of these are measures of productivity, they
are not always indicative of accomplishment or scientific
contribution.
It is easy to identify the factors which have contributed to
the perception that HTS achievements can be reduced to
productivity metrics. First, the sight of robotic arms
moving in a laboratory gives a strong visual impression
of productivity. In addition, unrealistic throughput
claims are often made by hardware vendors, screening
service providers and HTS team members to justify the
large financial investment required by large scale HTS.
Most obvious of all, the genuine success of HTS groups
themselves, sometimes demonstrating several-fold in-
creases in data output within a few years, has served to
elevate expectations for equivalent increases in the future.
The emphasis on numbers perpetuates two false assump-
tions: that all assays can be run with equal efficiency on
all robots, and that the only job of the HTS group is to
run assays. Only people who work in a laboratory within
a pharmaceutical company are aware of the great variety
of processes that could be referred to as a screen and that
some screens are more amenable to automation than
others. Biological components could include cells, en-
zymes, receptors, ion channels, transcription factors or
microorganisms, each of which has its own requirements
for handling and stability. At the biochemical level, a
screen may consist of an enzymatic reaction, binding of a
receptor to a ligand or a cellular activity (including
death). Performance of the screen may require pipetting
of different samples of different volumes, mixing, wash-
ing, centrifugation, filtration and incubation with regu-
lation of temperature, humidity and atmospheric gases.
The physical endpoint measured might be radioactivity,
spectrophotometry, luminescence, fluorescence, polarized
fluorescence or time resolved fluorescence. It is unlikely
that a single robotic system, even an entire laboratory,
could be prepared to meet all the possible contingencies
the next high-priority screen may demand. It is likely,
however, that an HTS group could perform many of the
permutations of screen designs described above. This
diversity of capability, however, will come at the expense
of throughput. The true measure of success of the HTS
group, therefore, is not merely the quantity of data
generated, but also the diversity of automation applica-
tions implemented which meet the needs of as many
individual scientist customers as possible.
The second incorrect assumption is that all the robotic
high throughput screening group does is run screens. In
reality, members of the robotic screening group are likely
to some extent, to repair broken equipment, give tours,
program and integrate robots and other automated
workstations, talk to scientist customers, analyse data,
order reagents, make presentations at project meetings,
evaluate new equipment and software, explore new tech-
nologies for future screens, develop the automated
method for the next screen and always be on call if
something goes wrong.
If numbers are the primary benchmark, all activities
other than running screens must be eliminated to avoid
the appearance of low productivity. To create a more
balanced view of productivity, additional metrics should
be considered including:
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Diversity of screens performed.
Low personnel turnover.
Publications and presentations by HTS staff.
Positive scientist customer feedback.
Teaching non-HTS scientists to apply automation.
Active new technology development projects.
Performing screens previously considered not feas-
ible.
Although it is necessary to generate more data against
more targets to increase the likelihood of finding more
chemical leads for development, many other factors
contribute to create a successful and productive HTS
group.
Progressmdoing the job better
While productivity measures how much of the job is
being done, progress is a measure of how productivity is
being improved. For HTS, this might be seen as bringing
more screens on line faster and running them with
greater throughput. A more general view of progress
would be any improvements in the infrastructure which
supports the HTS process.
The HTS infrastructure consists of the elements needed
for optimal productivity, which include:
Sample sourcing and plate handling.
Screen format and design
Robotic hardware
Data management
Each of these elements plays a critical role in efficient and
effective HTS. Most importantly, a deficiency in one
aspect of the infrastructure could easily eliminate the
value of achievement in all other areas.
The impact of sample sourcing and plate handling
becomes more critical as test sample collections continue
to grow through combinatorial chemistry and sample
acquisitions. Test sample plates need to be stored in an
appropriate manner, typically tightly sealed and frozen,
but the process of thawing and unsealing individual
microtitre plates is slow and usually manual. Bar coding
of each plate should be done in a way that is machine-
readable for real-time sample tracking, but also people-
readable for rapid recognition and sorting.
It is difficult for a small HTS group to perform efficiently
the large variety of possible screen formats and physical
endpoints. One option is to develop excellent biochemical
and automation expertise in a subset of standard assay
designs which could encompass most screens likely to be
encountered. Examples might include enzyme assays
with spectrophotometric or fluorescent endpoints,
ELISA assays and selected radioactive formats. These
core competency formats can serve as examples for future
HTS customers of how to create an assay which can
rapidly become a high throughput screen.
Robotic and automated hardware, in addition to being
reliable, must be integrated and utilized in a way which
improves productivity. In this regard, the common ar-
rangement with a central robotic arm carrying individual
microtiter plates among workstations is not optimal. It is
necessary to make robots work smarter, not harder.
Utilization of self-feeding devices such as stackers, eleva-
tors and conveyors can increase throughput whether used
manually or robotically. In addition scheduling of both
hardware and people can be modified to recover time
normally devoted to non-critical steps.
Diversity is what makes data management especially
difficult. Readers produce data in diverse formats with
non-standard headers. Data may consist of single or
multiple point determinations. Controls may be a single
well or a complete titration curve, possibly on a different
microtitre plate from test samples. A unified approach to
data management is needed to overcome this diversity
and streamline processing. Data files from all readers
should be converted to a standard format with well
defined headers which include sample and screen iden-
tity, intended calculation scheme, unique sequence num-
ber and time stamp. Processing the results from each
microtitre plate should occur as soon as the plate is read
as well as standard, automated quality assessments.
People--how it all happens
The best people in the HTS group usually have a diverse
set of skills and are very broadly trained. They must
routinely adapt to new ideas and face new challenges in
biochemical assay design, software, data management,
hardware trouble shooting and customer service. During
the early development of a novel screen they are expected
to take risks to find creative, efficient solutions, but
during screening they ought to be very consistent and
stable. They must handle all complaints from scientist
customers with speed and courtesy.
The scientist customers with which the HTS group inter-
act are, however, also people. They often require patient
education about HTS from HTS personnel. Scientist
customers are also under pressure because of their own
and their department’s priorities.
In conclusion--a few priorities
The fundamental challenge to the HTS group is to
provide excellent and timely screening services, but still
devote efforts to new technologies and personnel devel-
opment. To achieve this, priorities for the HTS group
might be divided into short-term and middle-term prio-
rities.
Short-term priorities need to be focused on speed and
throughput. The easiest screens should be performed
quickly, even at the expense of more difficult assays. It
is these simpler formats which are the basis for the core
competencies. The only exceptions are, of course, the few
screens assigned the highest priority by senior manage-
ment. Customer interactions need to be very frequent
such that all news, good or bad, is delivered now.
Middle-term priorities are focused on development of the
infrastructure, the people and scientist customers. Im-
provements to the infrastructure will always be required
to meet the expanding demand for HTS. This can only
be accomplished by letting the HTS staff find creative
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solutions. The people in HTS always need to learn more
and gain more experience. In time, the emphasis on a
breadth of knowledge will be replaced by examples of
excellent depth of knowledge to solve the most difficult
problems. Last of all, since HTS is frequently a service
function, it is essential to educate the scientist customer
about efficient assay design and the opportunities af-
forded by appropriate uses of automation.
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